GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

LY3532226

Company
Eli Lilly and Company
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
3 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

3 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Find a Clinical Trial Near Me

See recruiting studies for LY3532226 and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT06143956

    A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

    Not yet reported Eli Lilly and Company 1481 participants Est. completion 2028-02 56 sites Stand-alone
    Other conditions: Obesity, Overweight
    View official trial listing →
  • Recruiting NCT NCT07215559

    A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

    Not yet reported Eli Lilly and Company 200 participants Est. completion 2027-05 42 sites
    Type 2 diabetes Other conditions: Obesity, Overweight
    View official trial listing →
  • Recruiting NCT NCT07589608

    A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

    Not yet reported Eli Lilly and Company 400 participants Est. completion 2028-02 40 sites
    Other conditions: Overweight, Obesity
    View official trial listing →
  • Completed NCT NCT04923269

    A Study of LY3532226 in Healthy Participants

    Not yet reported Eli Lilly and Company 41 participants Est. completion 2021-10-28 1 site Stand-alone
    Other conditions: Healthy
    View official trial listing →
  • Completed NCT NCT05407961

    A Study of LY3532226 in Participants With Type 2 Diabetes Mellitus

    Not yet reported Eli Lilly and Company 90 participants Est. completion 2024-01-12 1 site Mixed
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT05887999

    A Study of LY3532226 in Participants With Type 1 Diabetes Mellitus

    Not yet reported Eli Lilly and Company 30 participants Est. completion 2024-02-21 1 site Stand-alone
    Other conditions: Diabetes Mellitus, Type 1
    View official trial listing →
  • Completed NCT NCT06557356

    A Study of LY3532226 in Participants With Obesity

    Not yet reported Eli Lilly and Company 132 participants Est. completion 2025-12-12 4 sites Stand-alone
    Other conditions: Obesity
    View official trial listing →
  • Not yet recruiting NCT NCT07765511

    A Study of Macupatide (LY3532226) in Participants With Obesity or Overweight Without Type 2 Diabetes

    Not yet reported Eli Lilly and Company 60 participants Est. completion 2027-06 3 sites
    Other conditions: Obesity, Overweight
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.